The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a 35-year-old man who has suffered from ulcerative colitis for 13 years.
Tremfya has been used in the past to treat plaque psoriasis and psoriatic arthritis. UChicago Medicine’s David Rubin, MD, led a global study that proved the treatment is also effective for ulcerative colitis. The study was a component of the FDA’s approval of the drug, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
